These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 18817364)
1. 3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase. Pettus LH; Xu S; Cao GQ; Chakrabarti PP; Rzasa RM; Sham K; Wurz RP; Zhang D; Middleton S; Henkle B; Plant MH; Saris CJ; Sherman L; Wong LM; Powers DA; Tudor Y; Yu V; Lee MR; Syed R; Hsieh F; Tasker AS J Med Chem; 2008 Oct; 51(20):6280-92. PubMed ID: 18817364 [TBL] [Abstract][Full Text] [Related]
2. Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase. Pettus LH; Wurz RP; Xu S; Herberich B; Henkle B; Liu Q; McBride HJ; Mu S; Plant MH; Saris CJ; Sherman L; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS J Med Chem; 2010 Apr; 53(7):2973-85. PubMed ID: 20218619 [TBL] [Abstract][Full Text] [Related]
3. Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold. Herberich B; Cao GQ; Chakrabarti PP; Falsey JR; Pettus L; Rzasa RM; Reed AB; Reichelt A; Sham K; Thaman M; Wurz RP; Xu S; Zhang D; Hsieh F; Lee MR; Syed R; Li V; Grosfeld D; Plant MH; Henkle B; Sherman L; Middleton S; Wong LM; Tasker AS J Med Chem; 2008 Oct; 51(20):6271-9. PubMed ID: 18817365 [TBL] [Abstract][Full Text] [Related]
4. Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase. Wurz RP; Pettus LH; Xu S; Henkle B; Sherman L; Plant M; Miner K; McBride H; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS Bioorg Med Chem Lett; 2009 Aug; 19(16):4724-8. PubMed ID: 19574047 [TBL] [Abstract][Full Text] [Related]
5. KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst J; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ Eur J Pharmacol; 2010 Apr; 632(1-3):93-102. PubMed ID: 20132813 [TBL] [Abstract][Full Text] [Related]
6. p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression. Aston NM; Bamborough P; Buckton JB; Edwards CD; Holmes DS; Jones KL; Patel VK; Smee PA; Somers DO; Vitulli G; Walker AL J Med Chem; 2009 Oct; 52(20):6257-69. PubMed ID: 19772287 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors. Wrobleski ST; Lin S; Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Gillooly KM; Shuster DJ; McIntyre KW; Doweyko AM; Kish KF; Tredup JA; Duke GJ; Sack JS; McKinnon M; Dodd J; Barrish JC; Schieven GL; Leftheris K Bioorg Med Chem Lett; 2008 Apr; 18(8):2739-44. PubMed ID: 18364256 [TBL] [Abstract][Full Text] [Related]
8. The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor. Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Schieven GL; Gillooly KM; Shuster DJ; Taylor TL; Yang X; McIntyre KW; McKinnon M; Zhang H; Marathe PH; Doweyko AM; Kish K; Kiefer SE; Sack JS; Newitt JA; Barrish JC; Dodd J; Leftheris K Bioorg Med Chem Lett; 2008 Mar; 18(6):1762-7. PubMed ID: 18313298 [TBL] [Abstract][Full Text] [Related]
9. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase. Wurz RP; Pettus LH; Henkle B; Sherman L; Plant M; Miner K; McBride HJ; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS Bioorg Med Chem Lett; 2010 Mar; 20(5):1680-4. PubMed ID: 20138761 [TBL] [Abstract][Full Text] [Related]
10. Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity. Angell R; Aston NM; Bamborough P; Buckton JB; Cockerill S; deBoeck SJ; Edwards CD; Holmes DS; Jones KL; Laine DI; Patel S; Smee PA; Smith KJ; Somers DO; Walker AL Bioorg Med Chem Lett; 2008 Aug; 18(15):4428-32. PubMed ID: 18614366 [TBL] [Abstract][Full Text] [Related]
11. 5-amino-pyrazoles as potent and selective p38α inhibitors. Das J; Moquin RV; Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Newitt JA; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K Bioorg Med Chem Lett; 2010 Dec; 20(23):6886-9. PubMed ID: 21035336 [TBL] [Abstract][Full Text] [Related]
12. Benzothiazole based inhibitors of p38alpha MAP kinase. Liu C; Lin J; Pitt S; Zhang RF; Sack JS; Kiefer SE; Kish K; Doweyko AM; Zhang H; Marathe PH; Trzaskos J; Mckinnon M; Dodd JH; Barrish JC; Schieven GL; Leftheris K Bioorg Med Chem Lett; 2008 Mar; 18(6):1874-9. PubMed ID: 18296051 [TBL] [Abstract][Full Text] [Related]
13. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity. Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858 [TBL] [Abstract][Full Text] [Related]
14. Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy. de Dios A; Shih C; López de Uralde B; Sánchez C; del Prado M; Martín Cabrejas LM; Pleite S; Blanco-Urgoiti J; Lorite MJ; Nevill CR; Bonjouklian R; York J; Vieth M; Wang Y; Magnus N; Campbell RM; Anderson BD; McCann DJ; Giera DD; Lee PA; Schultz RM; Li LC; Johnson LM; Wolos JA J Med Chem; 2005 Apr; 48(7):2270-3. PubMed ID: 15801819 [TBL] [Abstract][Full Text] [Related]
15. 3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta. Peifer C; Abadleh M; Bischof J; Hauser D; Schattel V; Hirner H; Knippschild U; Laufer S J Med Chem; 2009 Dec; 52(23):7618-30. PubMed ID: 19591487 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors. Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718 [TBL] [Abstract][Full Text] [Related]
17. The discovery of novel protein kinase inhibitors by using fragment-based high-throughput x-ray crystallography. Gill A; Cleasby A; Jhoti H Chembiochem; 2005 Mar; 6(3):506-12. PubMed ID: 15696598 [TBL] [Abstract][Full Text] [Related]
18. Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitors. Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly KM; Shuster DJ; Doweyko AM; Sack JS; Kish K; Kiefer SE; Newitt JA; Zhang H; Marathe PH; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K Bioorg Med Chem Lett; 2011 Aug; 21(15):4633-7. PubMed ID: 21705217 [TBL] [Abstract][Full Text] [Related]
19. Identification of triazolopyridazinones as potent p38α inhibitors. Herberich B; Jackson C; Wurz RP; Pettus LH; Sherman L; Liu Q; Henkle B; Saris CJ; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS Bioorg Med Chem Lett; 2012 Jan; 22(2):1226-9. PubMed ID: 22196117 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase. Lumeras W; Caturla F; Vidal L; Esteve C; Balagué C; Orellana A; Domínguez M; Roca R; Huerta JM; Godessart N; Vidal B J Med Chem; 2009 Sep; 52(17):5531-45. PubMed ID: 19678708 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]